nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.12.2016 | Review Article

Current and Emerging Therapies for Itch Management in Psoriasis

verfasst von: Carolyn Stull, Shoshana Grossman, Gil Yosipovitch

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Pruritus is a common and significant symptom among patients with psoriasis. Pruritus is often present beyond the borders of psoriatic plaques, and frequently affects the scalp and genital regions. Psoriatic itch may be severe and can profoundly affect quality of life and sleep, even in the context of mild-to-moderate disease. These features often make the treatment of psoriatic pruritus challenging. However, there are a variety of effective topical and systemic treatment modalities available to address this symptom. While there remains a need for treatments that specifically target psoriatic itch, newly licensed therapies including secukinumab, ixekizumab and apremilast have been shown to rapidly and effectively mediate itch reduction.

Psoriasis Fry L. Br J Dermatol. 1988;119(4):445–61.CrossRef

Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143(5):969–73.CrossRefPubMed

Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151(3):594–9.CrossRefPubMed

Reich A, Hrehorow E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90(3):257–63.CrossRefPubMed

Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.

Kimball AB, Edson-Heredia E, Zhu B, Guo J, Maeda-Chubachi T, Shen W, et al. Understanding the relationship between pruritus severity and work productivity in patients with moderate-to-severe psoriasis: sleep problems are a mediating factor. J Drugs Dermatol. 2016;15(2):183–8.PubMed

Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006;18(3):227–33.PubMed

O’Neill JL, Chan YH, Rapp SR, Yosipovitch G. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire. Acta Derm Venereol. 2011;91(5):537–40.CrossRefPubMed

Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014;70(2):390–1.CrossRefPubMed

10.

Czarnecka-Operacz M, Polanska A, Klimanska M, Teresiak-Mikolajczak E, Molinska-Glura M, Adamski Z, et al. Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations. Postepy Dermatol Alergol. 2015;32(6):426–30.CrossRefPubMedPubMedCentral

11.

Kimball AB, Naegeli AN, Edson-Heredia E, Lin CY, Gaich C, Nikai E, et al. Psychometric properties of the itch numeric rating scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016. doi:10.1111/bjd.14464.PubMed

12.

Stander S, Augustin M, Reich A, Blome C, Ebata T, Phan NQ, et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) special interest group scoring itch in clinical trials. Acta Derm Venereol. 2013;93(5):509–14.CrossRefPubMed

13.

Roblin D, Yosipovitch G, Boyce B, Robinson J, Sandy J, Mainero V, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–8.CrossRefPubMed

14.

Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–24.CrossRefPubMed

15.

Moynes DM, Vanner SJ, Lomax AE. Participation of interleukin 17A in neuroimmune interactions. Brain Behav Immun. 2014;41:1–9.CrossRefPubMed

16.

Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156(6):1272–7.CrossRefPubMed

17.

Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149(4):718–30.CrossRefPubMed

18.

Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a ‘hot’ medicine is reignited. Expert Opin Pharmacother. 2010;11(8):1359–71.CrossRefPubMed

19.

Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol. 1993;29(3):438–42.CrossRefPubMed

20.

Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–24.CrossRefPubMed

21.

Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol. 1999;79(2):118–21.CrossRefPubMed

22.

Stander S, Schurmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag. 2006;2(2):213–8.CrossRefPubMedPubMedCentral

23.

Senba E, Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res. 2004;50(3):257–62.CrossRefPubMed

24.

Stander S, Luger TA. Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt. 2003;54(5):413–7.CrossRefPubMed

25.

Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204(1):63–8.CrossRefPubMed

26.

Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol. 2015;226:337–56.CrossRefPubMed

27.

Kircik L. Salicylic acid 6 % in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. J Drugs Dermatol. 2011;10(3):270–3.PubMed

28.

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC. Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2013;27(4):399–410.CrossRefPubMed

29.

Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.PubMed

30.

Thirupathi A, Elango T, Subramanian S, Gnanaraj P. Methotrexate regulates th-1 response by suppressing caspase-1 and cytokines in psoriasis patients. Clin Chim Acta. 2016;30(453):164–9.CrossRef

31.

Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol. 2000;1(1):27–39.

32.

Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63(6):925–46 (quiz 947–8).

33.

Schewitz-Bowers LP, Lait PJ, Copland DA, Chen P, Wu W, Dhanda AD, et al. Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A. Proc Natl Acad Sci. 2015;112(13):4080–5.CrossRefPubMedPubMedCentral

34.

Schopf RE, Hultsch T, Lotz J, Brautigam M. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A. J Eur Acad Dermatol Venereol. 1998;11(3):234–9.CrossRefPubMed

35.

Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R. Low-dose, short-term ciclosporin (neoral(R)) therapy is effective in improving patients’ quality of life as assessed by skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol. 2011;38(5):465–72.CrossRefPubMed

36.

Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126(2):121–36.CrossRefPubMed

37.

Sola-Ortigosa J, Sanchez-Regana M, Umbert-Millet P. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatolog Treat. 2012;23(3):203–7.CrossRefPubMed

38.

Gottlieb A, Feng J, Harrison DJ, Globe D. Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(4):580–6.CrossRefPubMed

39.

Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192–9.CrossRefPubMed

40.

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74.CrossRefPubMed

41.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.CrossRefPubMed

42.

Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.CrossRefPubMed

43.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.CrossRefPubMed

44.

Kimball A, Nikai E, Zhu B, Carlier H, et al. Ixekizumab impact on itch severity compared to etanercept and placebo: results from UNCOVER-2, a phase 3 trial in patients with plaque psoriasis. J Invest Dermatol. 2015;135(Supplement 3):S19–S19.

45.

Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514–20.CrossRefPubMed

46.

Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–29.CrossRefPubMed

47.

Krueger J, Clark JD, Suarez-Farinas M, Fuentes-Duculan J, Cueto I, Wang CQ, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016;137(4):1079–90.CrossRefPubMed

48.

Mamolo CM, Bushmakin AG, Cappelleri JC. Application of the itch severity score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat. 2015;26(2):121–3.CrossRefPubMed

49.

Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015;26(1):19–22.CrossRefPubMed

50.

Papp K, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral JAK1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–76.CrossRefPubMed

51.

Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase 2a study. Br J Dermatol. 2016;174(5):985–95.CrossRefPubMed

52.

Lavery MJ, Stull C, Kinney MO, Yosipovitch G. Nocturnal pruritus: the battle for a peaceful night’s sleep. Int J Mol Sci. 2016;17(3). doi:10.3390/ijms17030425.

53.

Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manage. 2003;25(3):288–91.CrossRefPubMed

54.

Puzantian T. Mirtazapine, an antidepressant. Am J Health Syst Pharm. 1998;55(1):44–9.PubMed

55.

Stull C, Lavery MJ, Yosipovitch G. Advances in therapeutic strategies for the treatment of pruritus. Expert Opin Pharmacother. 2015;23:1–17.

56.

Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol. 1999;140(5):887–90.CrossRefPubMed

57.

Levin AA, Aleissa S, Dumont N, Martinez F, Donovan C, Au SC, et al. A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasis. J Drugs Dermatol. 2014;13(8):922–6.PubMed

58.

Evers AW, Kleinpenning MM, Smits T, Boezeman J, van de Kerkhof PC, Kraaimaat FW, et al. Itch and scratching as predictors of time to clearance of psoriasis with narrow-band ultraviolet B therapy. Br J Dermatol. 2009;161(3):542–6.CrossRefPubMed

59.

A one-year study to evaluate the effects and safety of CP-690,550 in patients with moderate to severe chronic plaque psoriasis [Internet]. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT01276639?sect=X0156_0506&term=A3921078&rank=1#outcome36.

Titel: Current and Emerging Therapies for Itch Management in Psoriasis
verfasst von: Carolyn Stull
Shoshana Grossman
Gil Yosipovitch
Publikationsdatum: 01.12.2016
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 6/2016
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-016-0213-5

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Medical Malpractice in Dermatology—Part I: Reducing the Risks of a Lawsuit

Nationwide Assessment of Cause-Specific Mortality in Patients with Rosacea: A Cohort Study in Denmark

Drug-Induced Tactile Hallucinations Beyond Recreational Drugs

Acknowledgement to Referees

Exercise-Induced Vasculitis: A Review with Illustrated Cases